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Abstract
Background Intravenous cyclophosphamide (IVCY)
has been used to treat severe lupus nephritis (LN) for
many years. Because of the wide variety of manifes-
tations of the condition and the long-term nature of the
disease, outcomes vary widely.
Objective To evaluate and compare the immediate
and long-term results of IVCY in pediatric onset
severe LN and between patients with normal and
abnormal initial renal function.
Methods Patients aged \18 years who attended the
Department of Pediatrics, Prince of Songkla Univer-
sity, diagnosed with severe LN, and who were given a
36-month IVCY course, were included. Comparison
of overall survival between the two groups was
assessed using Kaplan–Meier survival curves.
Results 108 patients with a mean age of 12.6 ± 2.7
years were studied, with a mean follow-up time of
5.7 ± 4.3 years. 48 patients completed the IVCY
course. 36 patients had abnormal renal function and 72
patients had normal renal function at the start of
therapy. Both groups responded well initially to
treatment; proteinuria reduced to normal levels after
1 and 2 treatments in the normal and abnormal groups,
respectively, while creatinine clearance returned to
normal levels after 8 treatments in the abnormal group.
Overall survival was not different between the two
groups; however, the abnormal renal function group
had a higher crude mortality rate than the normal
group (13/36 vs 10/72, p value = 0.02). At the time of
analysis, some patients who had completed their
IVCY course still required other therapy to control
their disease activity.
Conclusion Three years of IVCY treatment provided
similar outcomes in both normal and abnormal renal
function groups. Immediate outcomes were favorable
but long-term remission was not promising.
Keywords Lupus nephritis  Systemic lupus
erythematosus  SLE  Intravenous
cyclophosphamide  IVCY
Background
Systemic lupus erythematosus (SLE) is a life-threat-
ening illness which may lead to chronic disease
affecting multiple organs. Induction of rapid and
sustained remission is the optimal treatment result. In
recent decades, multiple immunosuppressive drugs,
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such as cyclophosphamide, azathioprine, cyclospor-
ine, or mycophenolate mofetil (MMF), have been
trialed in combination with corticosteroids in an
attempt to achieve long-term remission with minimal
side effects [1–4]. Renal involvement is a major
indicator of morbidity and mortality in SLE, and
pediatric onset SLE is known to be more serious than
in adult patients [5]. An ‘optimal therapy’ is difficult to
determine, as the disease has a wide variety of
manifestations [1, 6–8].
Currently, intravenous cyclophosphamide (IVCY)
is the recommended treatment in severe lupus nephri-
tis. Initial studies of IVCY therapy in severe lupus
nephritis showed quite good outcomes in both adults
and children; however, many subsequent studies with
longer patient follow-up found that their results were
not as good as the initial studies had promised with
many patients relapsing and developing unfavorable,
long-term side effects [9–13]. A preliminary report
from our institution involving 16 children treated with
IVCY showed satisfactory outcomes with minimal
complications; however, the duration of remission was
not evaluated due to the short follow-up period of that
study [14].
The objectives of this study were to evaluate and
compare the outcomes of IVCY treatment in child-
hood onset severe lupus nephritis in a large group of
Thai children and between patients with normal and
abnormal initial renal function.
Methods
This retrospective study examined the medical records
of patients diagnosed with SLE based on the American
Rheumatism Association 1982 revised criteria [15],
with LN WHO class IV or who had severe glomeru-
lonephritis, defined by rising serum creatinine or heavy
proteinuria, who had not responded to corticosteroid
therapy or corticosteroids combined with oral cyclo-
phosphamide. All patients who attended the Depart-
ment of Pediatrics, Prince of Songkla University
Hospital between October 1993 and December 2008
were included. During this period in our institution,
patients who had LN WHO class IV or severe
glomerulonephritis were offered a 36-month course
of IVCY therapy, totaling 17 treatments, monthly for 7
treatments followed by every 3 months for 10 treat-
ments. One treatment consisted of cyclophosphamide
in 100 ml of 5 % dextrose in water, administered
intravenously for 1 h at 500, 750, and 1,000 mg/body
surface area (BSA), on the first, second, and thereafter
treatments, respectively. At each treatment, a half
isotonic saline solution was infused for 24 h following
the treatment at 2,000 ml/m2/day to ensure the patient
did not become dehydrated and to avoid hemorrhagic
cystitis. 2-mercaptoethane sulfonate sodium (ME-
SNA) was not used in any patient.
Oral prednisolone and pulse methylprednisolone
were combined, adjusted to the clinical and serolog-
ical status of each individual patient, and antihyper-
tensive drugs and diuretics were given as required.
Treatment was temporarily suspended if the patient
developed infection, fever, or if the white blood cell
count (WBC) dropped below 3,000/mm3. Anti-emetic
drugs were prescribed to patients who experienced
nausea and vomiting.
Each patient’s weight, height, BSA, blood pressure,
urinalysis, complete blood count (CBC), 24-h protein
and creatinine, blood urea nitrogen, serum creatinine,
antinuclear antibodies (ANA), anti-double-strand-
DNA (anti-ds-DNA), and complement component 3
(C3) were measured before every treatment. 24-h urine
protein and creatinine levels were regarded as unre-
liable and excluded from analysis if urine creatinine
was less than 10 mg/kg/day or greater than 30 mg/kg/
day. Creatinine clearance (CCr) was calculated by a
standard formula using 24-h urine collection
(excluded as above if CCr greater than 250 ml/min/
1.73 m2).
The patients were divided into two groups, based on
the initial serum creatinine and creatinine clearance
levels—the first group being those with creatinine
clearance less than 90 ml/min/1.73 m2 or serum
creatinine level higher than the upper limit of the
normal range for age and sex (abnormal renal function
group), and the second group being the remaining
patients (normal renal function group), and the results
of treatment of the patients in the two groups were
compared at the end of the treatment course. The status
of medication, such as prednisolone or other immu-
nosuppressive drugs, at the time of analysis was used
to evaluate long-term treatment outcomes. Chronic
kidney disease (CKD) was defined if a patient had
abnormal renal function lasting for more than
6 months.
Statistical analysis was performed using R soft-
ware, version 2.10.1 [16]. Pearson’s chi-squared test
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or Fisher’s test as appropriate were used for testing
associations between two or more variables. Kaplan–
Meier survival curves were used to estimate and
compare survival rates, and the log-rank test was used
to compare survival curves between the two groups.
p values less than 0.05 were considered significant.
This study was conducted with the approval of the
Ethics Committee of Prince of Songkla University.
Results
During the study period, a total of 108 (19 male, 89
female) patients with a mean age at diagnosis of
11.4 ± 2.6 years (range 5.4–16.9) and age at start of
IVCY therapy 12.6 ± 2.7 years (range 5.5–20.6)
received corticosteroid treatment combined with
IVCY. The mean follow-up time was 5.7 ± 4.3 years
(median 3.6 years, range 30 days–14.7 years). 92
patients had LN class IV prior to starting treatment,
8 patients had LN class II but impaired renal function,
2 patients had LN class V with renal failure, 1 patient
had LN class III, and 5 patients had not had a biopsy.
There were 72 patients who had normal renal
function and 36 who had abnormal renal function (34
with creatinine clearance\90 ml/min/1.73 m2, 2 with
abnormally high creatinine level for age and sex).
Table 1 shows a comparison of patient characteristics,
baseline laboratory findings, LN classification, and
follow-up status at the end of the study between those
with initial abnormal renal function and those with
normal renal function. There were no significant
differences between the two groups in terms of sex,
age, and LN class; however, a higher proportion of
deaths occurred in the abnormal renal function group.
Baseline urinary protein levels were significantly
higher in the abnormal renal function group, while
hemoglobin and white blood cell levels were signif-
icantly lower.
Figure 1 shows the comparison of laboratory
findings of the two groups of patients during IVCY
therapy. Serum creatinine and creatinine clearance
were not changed during the period of therapy for
patients with normal renal function. For patients with
abnormal renal function, the creatinine level and
creatinine clearance gradually improved and reached
normal levels after the 8th treatment; however, only 20
of these patients completed the full course of 17
treatments. Proteinuria dramatically decreased after 1
treatment of IVCY in patients who had normal renal
function, while urinary protein decreased after 2
treatments of IVCY in patients who had abnormal
renal function.
Hemoglobin levels increased steadily in both
groups, more rapidly for the patients with abnormal
renal function; however, levels were lower initially in
this group. White blood cells were suppressed by
therapy in both groups. Platelets were steady and
within normal ranges among patients in the normal
renal function group; however, no patient had a
platelet count less than 100,000 cells/mm3.
In all cases, the ANA titer decreased immediately
after the first treatment and remained low until the end
of the course. C3 increased to normal levels after the
14th treatment in both groups.
Thirty-two patients developed acute kidney injury
(AKI), of whom 7 died, 18 resolved, and 7 progressed
to CKD. Two patients also had CKD at the time they
were first seen by us, but both died later after initiation
of the IVCY treatment.
Twenty-five patients had a repeat renal biopsy
performed after the end of their course of IVCY (within
100 days), of whom 10 LN class IV remained class IV,
13 LN class IV patients improved, one patient with LN
class IV progressed to end stage renal disease (ESRD),
and one LN class II remained LN class II.
The major complications of therapy were infections
and hemorrhagic cystitis. Secondary malignancy was
not found in any patients. Nausea and vomiting were
the most common side effects. Three patients who had
straight hair prior to IVCY treatment grew curly hair
after alopecia.
As shown in Table 1, at the end of the study,
twenty-three patients had died, 14 were referred to
other clinics, 10 patients were lost to follow-up, and 61
were still being followed. Forty-eight patients had
completed the full 17-treatment course of IVCY
therapy, and of the 26 who were also still being
followed up, 9 (19 %) were free of medication, 12
were on prednisolone alone, while 5 were on prednis-
olone plus one other immunosuppressive drug (1
azathioprine, 4 MMF). One patient who was on only
prednisolone at the end of the study had been treated
with azathioprine and MMF after completing the full
IVCY course but the proteinuria had persisted, while
one patient who had not received treatment for
inactive SLE developed ESRD and was subsequently
on dialysis.
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At the time of analysis, 31 patients were still
maintaining their treatment program, while 29 patients
had begun but not completed the full course: 15
patients had died, 2 had been referred to other clinics,
8 had been lost to follow-up, and 4 patients had had
their therapy terminated (two for severe vomiting, and
one each for hemorrhagic cystitis and ESRD).
Of the 48 cases who completed therapy, 30 patients
relapsed; 16 in the normal renal function group and 14
in the abnormal renal function group. The most
common site of relapse was renal related.
Figure 2 shows the patient survival curve of SLE
patients separated by initial renal function group
from the start of treatment with IVCY. There was
no significant difference in overall survival between
the two groups, although the crude mortality rate
was higher in the group of patients who had
abnormal renal function at the start of treatment
(10/72 vs 13/36, p value = 0.02). The overall
survival rates at 2 and 5 years were 93 %
(n = 77, 95 % CI: 87–98 %) and 78 % (n = 42,
95 % CI: 70–88 %), respectively. The median
survival time of the normal renal function group
was undefined. For the abnormal renal function
group, the median survival time was 8.7 years
(p = 0.15).
Table 1 Comparison of patient characteristics, baseline laboratory levels, initial LN classification, and follow-up status by initial
renal function group
Initial renal function Total p value
Normal Abnormal
Sex, N (%) 0.66
Male 14 (19.4) 5 (13.9) 19 (17.6)
Female 58 (80.6) 31 (86.1) 89 (82.4)
Age (years), mean (SD) 12.2 (2.5) 13.3 (2.9) 0.05
Baseline laboratory levels, median (IQR)
Urinary protein (mg/kg/day) 1,320 (355–2,257.5) 2,200 (1,090–3,670) 0.03
Creatinine clearance (mL/min/1.73 m2) 102.7 (93.9–123.2) 64.8 (57.6–83.2) \0.001
Creatinine (mg/dL) 0.7 (0.6–0.8) 0.9 (0.8–1.3) \0.001
Hemoglobin (g/dL) 10.9 (9.8–11.7) 9.1 (7.9–10.1) \0.001
WBC (cells/mm3) 9,400 (6,700–11,950) 6,700 (4,850–11,500) 0.046
Platelets (cells/mm3) 301,500 (240,750–373,000) 320,000 (160,000–364,000) 0.23
Antinuclear antibody (titer) 160 (35–640) 160 (35–640) 0.93
C3 (mg/dL) 52 (33.5–78.5) 40 (21–62.5) 0.86
LN Class, N (%) 0.16
II 4 (5.6) 5 (13.9) 9 (8.3)
III 0 (0) 1 (2.8) 1 (0.9)
IV 63 (87.5) 28 (77.8) 91 (84.3)
V 2 (2.8) 0 (0) 2 (1.9)
No biopsy 3 (4.2) 2 (5.6) 5 (4.6)
Completed IVCY course, N (%) 0.15
No 44 (61.1) 16 (44.4) 60 (55.6)
Yes 28 (38.9) 20 (55.6) 48 (44.4)
Follow-up time (years), median (IQR) 3.18 (1.47–5.46) 5.09 (3.58–6.77) 0.006
Status, N (%) 0.05
Alive 46 (63.9) 15 (41.7) 61 (56.5)
Lost to follow-up 7 (9.7) 3 (8.3) 10 (9.3)
Dead 10 (13.9) 13 (36.1) 23 (21.3)
Referred 9 (12.5) 5 (13.9) 14 (13.0)
Total 72 36 108
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Fig. 1 Comparison of serum creatinine, creatinine clearance,
urinary protein, hemoglobin, white blood cell count, platelet
count, C3, and antinuclear antibody over the 17-treatment course
of IVCY between patients with abnormal renal function (black)
and normal renal function (gray) (N = 36 vs 72)
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Discussion
Three years of therapy with IVCY is a long-term
treatment. In addition, SLE is not a common disease in
children, so a follow-up period of many years is
required in order to properly evaluate long-term
outcomes. Our study on the efficacy of IVCY in
pediatric onset SLE in a single center included both a
large number of patients and a long duration of follow-
up. We found that IVCY therapy during the acute
phase provided quite a good response in terms of
clinical activity of SLE, serum creatinine, creatinine
clearance, proteinuria, and serological activity of the
disease. The maintenance phase is as important as the
treatment stage, as the minimum dosage needs to be
the best achievable compromise between minimal
adverse reaction and optimal therapy.
Patients with abnormal renal function also achieved
a good initial response in terms of reduced proteinuria,
although these patients had a higher baseline level, and
it took longer for them to return to normal levels than
for patients with normal renal function. Creatinine
clearance took longer to return to normal levels than
proteinuria in patients with abnormal renal function.
Our study showed that IVCY can induce remission
of SLE, although it is rarely long-term in the context of
such a chronic disease, with the disease reawakening
in many cases. A similar study in adults [17], and one
by Al Salloum et al. [18] in 9 children (4 LN III, 5 LN
IV), showed improvement of renal function during
treatment but the improvement was not sustained—5
patients developed CKD within 2 years after com-
pleting the 3-year IVCY course (follow-up time
[5 years from the beginning of IVCY treatment).
An earlier study we conducted involving 21 of our
patients, of which 16 completed the 17-treatment
course over three years and were then followed up for
a median of 6.3 years, showed that after a few months
of therapy, hemoglobin, proteinuria, and serology tests
dramatically improved but serum creatinine and
creatinine clearance did not [14].
Lehman and Onel [19] reported that in 16 children
with lupus nephritis treated with 3 years of IVCY, the
renal biopsy activity index significantly improved
(p \ 0.001), the mean 24-h urine protein significantly
decreased (p \ 0.05), and the mean creatinine clear-
ance significantly increased (p \ 0.01). The results of
our treatments were not as good in terms of improved
LN classifications. In the Lehman and Onel study, all
11 LN class IV cases changed, with most improving, 3
to LN V, 1 to LN III, 6 to LN II, and 1 to LN I [19]. Our
study had 25 repeat renal biopsies after the complete
17-treatment course of IVCY, but only 13 patients
with LN class IV changed to other classes (11 had no
change and one progressed to ESRD).
In our previous study, LN class IV patients had a
similar outcome compared to LN class II patients,
indicating that our treatment regimen for LN class IV
patients was effective, as in general LN class IV
patients have a poorer prognosis than LN class II
patients [20].
Infection is a common complication in SLE patients
treated with IVCY therapy, as we previously reported,
with opportunistic infections being the most common
[21]. Severe infections were found in 36.9 % (31/84)
of those cases, of whom 13 died (41.9 %). Fungal and
Gram negative bacteria were the most common
organisms responsible for severe infection. Pulse
methylprednisolone usage, fungal infection, and renal
failure were significant risk factors for mortality [21].
Although there was no difference in survival rates
between the two groups, as assessed by the log-rank
test, the crude mortality rate in the impaired renal
function group was significantly higher. A likely
reason for this is that these patients would have
progressed to end stage renal failure, and in our
institution, long-term dialysis and renal transplantation
Fig. 2 Survival curve of SLE patients treated with IVCY by
initial renal function group
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are not routinely performed. Chronic dialysis and renal
transplantation for children in Thailand are still limited
for economic reasons, which inevitably make the
mortality rate higher than in countries with more
resources.
Although cyclophosphamide has been reported to
cause secondary malignancy, it is difficult to differ-
entiate this from other possible causes. Malignancy
was not identified in any patients in our study;
however, the follow-up time was probably too short
for malignancy to develop.
Ovarian dysfunction secondary to IVCY therapy
could not be assessed since our patients were mostly
teenagers, and although irregularity of menstruation
was noted, this is not uncommon in this age group so
any possible relationship with the treatment could not
be assessed. In our study, out of 26 patients who
completed the 17-treatment course and were alive at
the time of analysis, 24 were girls with a median age of
21 years. Two were aged less than 15 years. At least
three patients out of 22 potentially fertile women
became pregnant after therapy; thus, it is clear that
IVCY therapy does not guarantee ovarian dysfunction
in this age group. A study in Chinese adults showed
that older age and higher accumulative doses of
cyclophosphamide were independent risk factors of
ovarian failure [22]. Another study in 19 females with
an average age of 24 years found that 3 patients had
ovarian failure, while 3 achieved full-term pregnancy
[23]. Other side effects were also not assessed in this
study due to the small sample size. Studies with larger
patient numbers and long-term follow-up are required
to fully investigate this issue.
In our preliminary study of 20 patients, patient
survival at 5 years was 87 % (95 % CI 59–97) [14]. In
this larger and longer study, the rate was only slightly
smaller (78 %, 95 % CI 70–88). However, such good
results depend on completing the lengthy 36-month
IVCY therapy, and this is not easily achieved for
various reasons. Additionally, some patients die
during treatment, and many drop out either due to
being referred to other clinics or lost to follow-up. In
our study, less than 50 % of those who started
treatment could be evaluated at 5 years.
This retrospective study on a group of Thai children
has some limitations. First, the severity of LN varied
widely, and thus, other therapies were added to IVYC
according to the disease exacerbation. Second, many
children were referred elsewhere, such as other clinics,
after completion of treatment, due to entering adult-
hood or for other reasons. Third, there may have been
other factors that were not collected or measured
which could not be controlled for in the analysis.
Finally, the follow-up rate after 5 years was poor due
to families moving to other areas of the country.
Conclusion
IVCY combined with steroid therapy in Thai pediatric
onset severe lupus nephritis patients, initially with
both impaired and normal renal function, achieved a
favorable outcome in terms of induction of disease
remission and stability of disease during maintenance
therapy. However, the long-term outcome after ther-
apy is still less than satisfactory; although some
patients remained medication free for many years of
follow-up at the end of study, most required a return to
medication to control their disease activity.
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